!!! New Study Publication!!!
"Active Chest Tube Clearance Added to an Enhanced Recovery After Cardiac Surgery (ERAS) Program Improves Outcomes and Reduces Resource Utilization"


Adding PleuraFlow’s Active Chest Tube Clearance (ATC) to an ERAS cardiac surgery program reduced Retained Blood Syndrome by 41%, postoperative atrial fibrillation (POAF) by 17%, and ICU time by 30% in 684 patients compared to 650 controls, improving outcomes and resource utilization. (Gerdisch, et al, 2025)

Blog

BlogArticle

Initial Commercialization Efforts

Our lead product, the PleuraFlow® Active Tube Clearance® System is now available for marketing in the US, Canada and Europe. The board has worked with the executive team to lay out a strategy for the commercial roll out in 2011. The interest level by the surgeons and nurses is strong. The interest level by prospective distribution partners has been large and our global director of sales and marketing has been working interview and select the best of breed distributors as we get our start. The initial strategy is to contract with a select group of highly skilled, connected and motivated distributors in key markets to obtain the foundation for deeper account penetration as we prepare to expand for a broader market roll out. The company has signed and trained distributors in Canada, Germany, Austria and Italy, and working to finalize agreements with the first cohort of distributors in the US after a productive meeting with many of them at the STS.